SCHEMBL9488558

SCHEMBL9488558

Cc1ccc2nc(-c3ccc(C#N)cc3)cn2c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 12/20 0.73
RAB9A P51151 11/20 0.73
KDM4E B2RXH2 10/20 0.73
ALDH1A1 P00352 10/20 0.73
SMN1; SMN2 Q16637 9/20 0.73
PAX8 Q06710 2/20 0.73
KMT2A Q03164 2/20 0.73
MEN1 O00255 1/20 0.73
MITF O75030 1/20 0.73
KDM5A P29375 1/20 0.73
KDM5C P41229 1/20 0.73
ALDH1A3 P47895 4/20 0.69
APP P05067 3/20 0.66
HPGD P15428 5/20 0.62
PKM P14618 4/20 0.62
TP53 P04637 2/20 0.62
HSD17B10 Q99714 2/20 0.62
TSHR P16473 1/20 0.62
CDK5 Q00535 1/20 0.62
CDK5R1 Q15078 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL1691812 0.98 NPC1 (0.71) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL6320343 0.98 ALDH1A3 (0.72) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL2128252 0.91 APP (0.74) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL4954009 0.87 ALDH1A3 (0.88) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL4952001 0.87 ALDH1A3 (0.78) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL396368 0.85 NPC1 (1.00) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL2431086 0.83 ALDH1A3 (0.68) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL2427884 0.83 ALDH1A3 (0.68) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL2429882 0.83 ALDH1A3 (0.68) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL6320351 0.82 ALDH1A3 (0.70) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine UNIVERSITY OF HEIDELBERG (DE) 2020-02-27 US claimed
EP-3611256-A1 APPLICATION OF IMIDAZOPYRIDINE DERIVATIVES IN REGENERATIVE MEDICINE Universität Heidelberg (DE) 2020-02-19 EP claimed
CN-110981868-B Imidazopyridine compound, pharmaceutical composition containing compound, preparation method and application thereof SUN YAT-SEN UNIVERSITY (CN) 2021-08-31 CN disclosed
CN-110981868-A Imidazopyridine compound, pharmaceutical composition containing compound, preparation method and application thereof 中山大学 2020-04-10 CN disclosed
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine UNIVERSITY OF HEIDELBERG (DE) 2020-02-27 US disclosed
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine UNIVERSITY OF HEIDELBERG (DE) 2020-02-27 US disclosed
EP-3611256-A1 APPLICATION OF IMIDAZOPYRIDINE DERIVATIVES IN REGENERATIVE MEDICINE Universität Heidelberg (DE) 2020-02-19 EP disclosed
EP-3611256-A1 APPLICATION OF IMIDAZOPYRIDINE DERIVATIVES IN REGENERATIVE MEDICINE Universität Heidelberg (DE) 2020-02-19 EP disclosed
US-5204352-A 5-Guanylhydrazonylphenyl-2,3-alkyleneimidazol-1-ium and derivatives; Trypanosoma THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) 1993-04-20 US disclosed
US-4990506-A Sedatives, anxiolytic, antiulcer, antistress SYNTHELABO (FR) 1991-02-05 US disclosed
US-4891371-A HYPNOTIC, ANXIOLYTIC, ANTI-STRESS ULCER SYNTHELABO (FR) 1990-01-02 US disclosed
US-4767755-A NERVOUS SYSTEM DISORDERS SYNTHELABO (FR) 1988-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine DOT1L, NSD1, KDM3A NPC1 4209/4885RAB9A 3350/4885KDM4E 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.